22nd Century Group to Participate in the HC Wainwright Conference on September 15, 2026
MWN-AI** Summary
22nd Century Group, Inc. (Nasdaq: XXII), a leader in the tobacco harm reduction movement, will participate in the HC Wainwright Conference on September 15, 2026, at the Lotte New York Palace Hotel. The company's CEO Larry Firestone and CFO Dan Otto will attend the event, where investors can engage with management and access an updated investor presentation on their website.
Founded with a mission to combat the harms of smoking linked to nicotine addiction, 22nd Century Group has pioneered innovative technologies for reduced nicotine tobacco plants. Their proprietary, non-GMO tobacco varieties contain 95% less nicotine than conventional tobacco, enabling smokers to manage their nicotine consumption more effectively. The company's extensive patent portfolio supports the scalable commercial production of their unique tobacco varieties, ensuring ongoing leadership in tobacco harm reduction.
The flagship products, VLN® and Pinnacle VLN® cigarettes, provide smokers with a low-nicotine alternative, allowing them to reduce their nicotine intake while still enjoying a traditional smoking experience. Notably, VLN® cigarettes are the only low-nicotine combustible cigarettes authorized by the FDA in the U.S., offering smokers a proven method to decrease their nicotine consumption.
As part of its forward-looking strategy, 22nd Century Group continues to focus on regulatory compliance and ongoing development of its intellectual property, aiming to expand its market presence. However, the company cautions that forward-looking statements about its performance and prospects may differ from actual results due to various risk factors outlined in their recent financial filings.
Investors and stakeholders interested in learning more can connect with the company through their official channels, including social media platforms and their dedicated investor website.
MWN-AI** Analysis
**Market Analysis and Advice: 22nd Century Group (Nasdaq: XXII)**
As we approach the HC Wainwright Conference on September 15, 2026, opportunities for investors in 22nd Century Group present themselves amid a compelling narrative of innovation and regulatory navigation within the tobacco industry. 22nd Century Group is distinctly positioned within the market, being the first to develop reduced nicotine tobacco plants that significantly lower nicotine content—95% less than traditional tobacco, offering a practical solution to addiction through lower-risk alternatives.
The company's participation in this conference, particularly featuring notable executives like CEO Larry Firestone and CFO Dan Otto, offers a critical platform for them to showcase recent advancements and strategic initiatives. Investors should closely monitor outcomes from the conference, particularly any updates regarding sales performance, regulatory developments, and intellectual property enhancements that bolster their competitive edge.
The FDA authorization of VLN® cigarettes as the only low nicotine combustible option underscores a strategic advantage in the market that could propel growth prospects, differentiating the company from competitors. This unique positioning not only attracts regulatory backing but also appeals to a growing consumer segment prioritizing harm reduction.
Despite promising fundamentals, investors should remain vigilant regarding potential risks. The company's reliance on forward-looking statements indicates possible volatility in operational execution and market conditions. Evaluating factors like regulatory changes and market acceptance will be crucial in the short to medium term.
In conclusion, while 22nd Century Group shows significant promise with its pioneering technology and FDA backing, informed investment decisions should weigh potential high returns against inherent risks. Attending the HC Wainwright Conference could provide valuable insights and clarity on the company’s trajectory, making it an optimal time for investors to assess their positions in light of 22nd Century's strategic direction.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
MOCKSVILLE, N.C., Aug. 18, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), the only tobacco products company that has for 28 years led and continues to lead the fight against the harms of smoking driven by nicotine addiction, today announced that it will participate in the HC Wainwright Conference on September 15, 2026 at the Lotte New York Palace Hotel. Investors can register and request meetings with management via their HC Wainwright representative.
Attending the conference will be Larry Firestone, chairman and chief executive officer, and Dan Otto, chief financial officer.
The Company has posted an updated investor presentation online at https://ir.xxiicentury.com/.
About 22nd Century Group, Inc.
22nd Century Group is pioneering the tobacco harm reduction movement by enabling smokers to take control of their nicotine consumption.
Our Technology is Tobacco
Our proprietary non-GMO reduced nicotine tobacco plants were developed using our patented technologies that regulate alkaloid biosynthesis activities resulting in a tobacco plant that contains 95% less nicotine compared to traditional tobacco plants. Our extensive patent portfolio has been developed to ensure that our high-quality tobacco can be grown commercially at scale. We continue to develop our intellectual property to ensure our ongoing leadership in the tobacco harm reduction movement.
Our Products
We created our flagship low nicotine cigarette products, the VLN® cigarette and Pinnacle VLN® cigarette using our low nicotine tobacco, to give traditional cigarette smokers an authentic and familiar alternative in the form of a combustible cigarette that helps them take control of their nicotine consumption. Our VLN® cigarettes are the lowest nicotine cigarettes in America™ and have 95% less nicotine compared to traditional cigarettes and have been proven to allow consumers to greatly reduce their nicotine consumption.
FDA Authorized
Our VLN® cigarettes are the only low nicotine combustible cigarette authorized by the FDA in the United States.
VLN® is a registered trademark of 22nd Century Limited LLC.
Learn more about 22nd Century at xxiicentury.com, on X (formerly Twitter), on LinkedIn, and on YouTube.
Learn more about VLN® cigarettes at tryvln.com.
Cautionary Note Regarding Forward-Looking Statements
Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements, including but not limited to our full year business outlook. Forward-looking statements typically contain terms such as “anticipate,” “believe,” “consider,” “continue,” “could,” “estimate,” “expect,” “explore,” “foresee,” “goal,” “guidance,” “intend,” “likely,” “may,” “plan,” “potential,” “predict,” “preliminary,” “probable,” “project,” “promising,” “seek,” “should,” “will,” “would,” and similar expressions. Forward-looking statements include, but are not limited to, statements regarding (i) our cost reduction initiatives, (ii) our expectations regarding regulatory enforcement, including our ability to receive an exemption from new regulations, and (iii) our financial and operating performance. Actual results might differ materially from those explicit or implicit in forward-looking statements. Important factors that could cause actual results to differ materially are set forth in “Risk Factors” in the Company’s Annual Report on Form 10-K filed on March 26, 2026 and Quarterly Reports on Form 10-Q filed on May 7, 2026 and August 14, 2026. All information provided in this release is as of the date hereof, and the Company assumes no obligation to and does not intend to update these forward-looking statements, except as required by law.
Investor Relations & Media Contact
Daniel Otto
Chief Financial Officer & Investor Relations
22nd Century Group
investorrelations@xxiicentury.com
FAQ**
How does 22nd Century Group Inc XXII plan to leverage its proprietary non-GMO reduced nicotine tobacco technology in future product innovations?
What specific regulatory challenges does 22nd Century Group Inc XXII anticipate regarding their FDA-authorized VLN® cigarettes in the coming years?
Can 22nd Century Group Inc XXII discuss their strategic goals for expanding market presence and consumer awareness of VLN® cigarettes?
What insights does 22nd Century Group Inc XXII expect to share during the upcoming HC Wainwright Conference that could impact investor confidence?
**MWN-AI FAQ is based on asking OpenAI questions about 22nd Century Group Inc (NASDAQ: XXII).
NASDAQ: XXII
XXII Trading
-1.25% G/L:
$1.9947 Last:
8,218 Volume:
$2.01 Open:
XXII Latest News
